Semaglutide's Long-Term impact on heart and kidneys under Real-World microscope

NCT ID NCT07424430

Not yet recruiting Knowledge-focused Sponsor: LMC Diabetes & Endocrinology Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will analyze medical records of 400 adults with type 2 diabetes or obesity to see how semaglutide affects blood sugar, heart, and kidney health over three years. Researchers will compare those taking semaglutide to those on other diabetes medications. The goal is to understand how well semaglutide works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this study could provide real-world evidence on how semaglutide improves blood sugar, heart, and kidney health over time.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It has not started yet and relies on existing medical records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES (DM) OBESITY (DISORDER) TYPE 2 DIABETES

More trials for these conditions

Other studies related to the condition(s) this trial covers.